14 months in and retatrutide is still the thing I get wrong
Check-in as promised in the title: 14 months in and retatrutide is still the thing I get wrong. 14 months — those are the numbers, and they are the ones I am willing to defend. It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the…
research-use-only material is not approved for human use, full stop
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.
Sceptical of the extrapolation.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
the phase 2 numbers were striking and they were also 48 weeks in a small population
the phase 2 numbers were striking and they were also 48 weeks in a small population
honest_syringe33 is right about the escalation being the variable. It explains most of the difficult reports here.
Is that the 48-week figure or an earlier readout?
Sceptical of the extrapolation.
This is the sentence the rest of the board should read first. Phase 2 is not a label.